GLPwatch
Dulaglutide as a demethylating agent to improve the outcome of breast cancer.
Epigenomics · 2023
Last updated 2026-05-28In lab tests, the diabetes drug dulaglutide increased the activity of certain genes in breast cancer cells by up to four times by removing chemical markers that normally block their function. When combined with half the usual dose of the chemotherapy drug methotrexate, dulaglutide helped slow tumor growth more than methotrexate alone.
AI summary of the abstract below.
| Journal | Epigenomics, 2023 |
|---|---|
| Citations | 5 |
| Relative citation ratio | 0.63 |
| NIH percentile | 35 |
| Molecules | dulaglutide |
Abstract
Dulaglutide emerged as a promising therapeutic option for diabetes mellitus Type 2 (DM2). Owing to epigenetic similarities between the pathophysiology of DM2 and breast cancer (BC), we investigated the antitumor effect of dulaglutide. To investigate the effect of dulaglutide, we analyzed the expression of methylated gene promoter regions in BC (, and ). Dulaglutide increased the expression of , and up to fourfold in the MDA-MB-231 lineage by demethylating the gene promoter regions. This effect was translated to antitumoral activity and revealed significant tumor inhibition by combining the half-dose of methotrexate with dulaglutide. This therapy may mitigate the severe side effects commonly associated with chemotherapy.
Verbatim abstract via PubMed 38174426 ↗
Related research
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
- Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
- Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
- Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
- Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).
- Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).
- Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).